Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Normal total bilirubin in adults is generally 0.1 to 1.2 mg/dL, with direct (conjugated) bilirubin at 0.1 to 0.3 mg/dL and indirect (unconjugated) bilirubin at 0.2 to 0.8 mg/dL, while newborns are measured against much higher, age-specific thresholds. Elevated bilirubin, called hyperbilirubinemia, may point to liver conditions such as hepatitis or cirrhosis, blocked bile ducts from gallstones, accelerated red blood cell breakdown (hemolysis), or a harmless inherited variation like Gilbert syndrome, and visible jaundice typically begins above roughly 2.5 to 3 mg/dL. Reference ranges vary by laboratory, age, and testing method, and the pattern of direct versus indirect elevation matters as much as the total number, so see below for the full breakdown before drawing conclusions.
Because a single high bilirubin result can mean anything from a benign genetic trait to a problem needing prompt evaluation, it helps to look at your result alongside your actual symptoms, such as yellowing skin or eyes, dark urine, pale stools, fatigue, itching, or abdominal pain. Take a free, instant, online symptom check to see which causes best match your situation and to understand what questions and next steps to bring to your doctor.
Last reviewed for medical accuracy: 09/23/2026
Bilirubin is a yellow pigment produced during the breakdown of old red blood cells. Your liver processes bilirubin and sends it to your intestines for elimination. Measuring bilirubin levels provides key insights into liver function, red blood cell turnover and bile flow. Below is an overview of normal bilirubin levels, potential causes of elevated results and next steps if you have concerns.
Laboratories typically report three bilirubin measurements:
Total bilirubin
– Includes both direct (conjugated) and indirect (unconjugated) bilirubin.
– Normal range: 0.1 to 1.2 mg/dL (milligrams per deciliter).
Direct (conjugated) bilirubin
– Water-soluble form processed by the liver.
– Normal range: 0.0 to 0.3 mg/dL.
Indirect (unconjugated) bilirubin
– Fat-soluble form circulating before liver processing.
– Calculated by subtracting direct from total.
– Normal range: 0.2 to 0.8 mg/dL.
Reference ranges can vary slightly between labs. Always compare your results to the lab’s specific reference values.
Assessing bilirubin levels helps in:
Monitoring liver health
Elevated bilirubin may indicate impaired liver function.
Detecting hemolysis
Fast red blood cell breakdown raises indirect bilirubin.
Evaluating bile flow
Blockages in bile ducts increase direct bilirubin.
High bilirubin—also called hyperbilirubinemia—can stem from three main mechanisms:
Pre-hepatic (before the liver)
– Excessive red blood cell destruction (hemolysis).
– Causes: certain anemias (e.g., sickle cell), transfusion reactions, inherited enzyme deficiencies (e.g., G6PD deficiency).
Hepatic (within the liver)
– Impaired bilirubin processing by liver cells.
– Causes: viral hepatitis, alcoholic liver disease, cirrhosis, genetic syndromes (e.g., Gilbert’s, Crigler-Najjar).
Post-hepatic (after the liver)
– Blocked bile ducts preventing bilirubin excretion.
– Causes: gallstones, tumors in bile ducts or pancreas, strictures.
Gilbert’s syndrome
A mild genetic condition causing intermittent indirect bilirubin elevations. Often requires no treatment.
Viral hepatitis
Inflammation from hepatitis A, B or C can disrupt bilirubin processing.
Alcoholic liver disease
Chronic alcohol use damages liver cells, leading to elevated bilirubin.
Gallstones
Obstruction in the bile ducts causes a rise in direct bilirubin.
Hemolytic anemia
Accelerated red blood cell breakdown elevates indirect bilirubin.
Drug-induced liver injury
Certain medications (e.g., acetaminophen overdose, some antibiotics) can impair liver function.
A mild bilirubin rise may be detected only on blood tests. Higher levels can lead to:
These symptoms don’t always correlate precisely with the bilirubin number but signal the need for evaluation.
If your bilirubin levels are elevated, your healthcare provider may recommend:
Repeat blood tests
To confirm the finding and track trends.
Liver function tests (LFTs)
Including ALT, AST, alkaline phosphatase and albumin.
Complete blood count (CBC)
To look for anemia or signs of hemolysis.
Viral hepatitis panel
To detect hepatitis A, B or C infections.
Imaging studies
Ultrasound or MRI to check for gallstones, tumors or bile duct blockages.
Genetic testing
If conditions like Gilbert’s or Crigler-Najjar syndrome are suspected.
Treatment depends on the underlying cause:
Gilbert’s syndrome
Generally doesn’t require treatment. Lifestyle measures like avoiding fasting and dehydration can help.
Hemolytic anemia
Addressed with steroids, immunosuppressants or treatments specific to the type of anemia.
Viral hepatitis
Antiviral medications, rest, hydration and monitoring.
Gallstones or bile duct obstruction
May require endoscopic or surgical removal of stones or tumors.
Drug-induced injury
Stopping the offending medication and supportive care.
While mild elevations can be monitored, seek urgent care if you experience:
These could indicate serious liver failure, bile duct infection (cholangitis) or other life-threatening conditions. Always speak to a doctor about anything that could be serious or life-threatening.
If you’re unsure whether your symptoms or bilirubin test results need immediate attention, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you understand possible causes and suggest next steps in plain language.
If you have questions about your bilirubin levels or related symptoms, talk to your healthcare provider. Early evaluation and management can help address any issues before they become more serious.
(References)
* Maisels MJ, Gifford K. Normal serum bilirubin levels in the newborn and the effect of breast-feeding. Pediatrics. 1986 Nov;78(5):837-43. PMID: 3763296.
* Ahlfors CE. Bilirubin-albumin binding and free bilirubin. J Perinatol. 2001 Dec;21 Suppl 1:S40-2; discussion S59-62. doi: 10.1038/sj.jp.7210631. PMID: 11803415.
* Bertini G, Rubaltelli FF. Non-invasive bilirubinometry in neonatal jaundice. Semin Neonatol. 2002 Apr;7(2):129-33. doi: 10.1053/siny.2002.0100. PMID: 12208097.
* Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005 Feb 1;172(3):367-79. doi: 10.1503/cmaj.1040752. PMID: 15684121; PMCID: PMC545762.
* Watchko JF. Vigintiphobia revisited. Pediatrics. 2005 Jun;115(6):1747-53. doi: 10.1542/peds.2004-1748. PMID: 15930239.
* Holbrook I, Beetham R, Cruickshank A, Keir G, Watson I. Subarachnoid haemorrhage. Lancet. 2007 Mar 17;369(9565):904. doi: 10.1016/S0140-6736(07)60442-5. PMID: 17368148.
* Rödöö P, Ridefelt P, Aldrimer M, Niklasson F, Gustafsson J, Hellberg D. Population-based pediatric reference intervals for HbA1c, bilirubin, albumin, CRP, myoglobin and serum enzymes. Scand J Clin Lab Invest. 2013 Aug;73(5):361-7. doi: 10.3109/00365513.2013.783931. Epub 2013 Apr 12. PMID: 23581477.
* Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE, GLOBAL PBC Study Group. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol. 2020 Jul;115(7):1066-1074. doi: 10.14309/ajg.0000000000000557. PMID: 32618657.
* D'Antiga L, Beuers U, Ronzitti G, Brunetti-Pierri N, Baumann U, Di Giorgio A, Aronson S, Hubert A, Romano R, Junge N, Bosma P, Bortolussi G, Muro AF, Soumoudronga RF, Veron P, Collaud F, Knuchel-Legendre N, Labrune P, Mingozzi F. Gene Therapy in Patients with the Crigler-Najjar Syndrome. N Engl J Med. 2023 Aug 17;389(7):620-631. doi: 10.1056/NEJMoa2214084. PMID: 37585628.
* Merino-Andrés J, Pérez-Nombela S, Álvarez-Bueno C, Hidalgo-Robles Á, Ruiz-Becerro I, Fernández-Rego FJ. Neonatal hyperbilirubinemia and repercussions on neurodevelopment: A systematic review. Child Care Health Dev. 2024 Jan;50(1):e13183. doi: 10.1111/cch.13183. Epub 2023 Oct 16. PMID: 37842871.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.